patients with metastatic castration-resistant prostate cancer

FDA grants Fast Track designation to ARX517 for metastatic castration-resistant prostate cancer

FDA grants Fast Track designation to ARX517 for metastatic castration-resistant prostate cancer

The FDA has granted accelerated designation to ARX517 for use as a potential treatment option in patients with metastatic castration-resistant prostate cancer (mCRPC) who experience disease progression on an androgen receptor (AR) pathway inhibitor.1 An antibody-drug conjugate (ADC), ARX517 consists of a fully humanized prostate-specific membrane antigen (PSMA) monoclonal antibody that is bound to AS269. …

FDA grants Fast Track designation to ARX517 for metastatic castration-resistant prostate cancer Read More »

Olaparib Enhances Lutetium Lu 177 Vipivotide Tetraxetan Activity in mCRPC

Olaparib Enhances Lutetium Lu 177 Vipivotide Tetraxetan Activity in mCRPC

Shahneen Sandhu, PhD, MBBS, FRACP Enhanced antitumor activity was demonstrated with the addition of the PARP inhibitor olaparib (Lynparza) to the lutetium radioligand Lu 177 vipivotide tetraxetan (Pluvicto; formerly 177Lu-PSMA-617) in patients with metastatic castration-resistant prostate cancer (mCRPC), according to early results from the Phase 1 LuPARP study (NCT03874884).1 Among 32 patients treated at various …

Olaparib Enhances Lutetium Lu 177 Vipivotide Tetraxetan Activity in mCRPC Read More »

Scroll to Top